表紙
市場調查報告書

膀胱過動症治療藥的全球市場:2020年∼2024年

Global Overactive Bladder Therapeutics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 954856
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
膀胱過動症治療藥的全球市場:2020年∼2024年 Global Overactive Bladder Therapeutics Market 2020-2024
出版日期: 2020年08月19日內容資訊: 英文 120 Pages
簡介

膀胱過動症治療藥的全球市場在2020年∼2024年間,預測將成長到3億1117萬美元,在預測期間中預計將以2%的年複合成長率增長。

市場成長的主要因素有醫藥品的認證數量及策略性聯盟的增加。

本報告提供膀胱過動症治療藥的世界市場調查,提供市場形勢和規模,波特的五力分析,各產品的市場區隔,客戶和各地區形勢,業者情勢,供應商分析等資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:2019年-2024年的預測

波特的五力分析

市場區隔:各產品

  • 市場區隔
  • 各產品比較
  • 抗膽鹼劑:市場規模與預測(2019年∼2024年)
  • β3-腎上腺素受體激動劑:市場規模與預測(2019年∼2024年)
  • 其他膀胱過動症(OAB)治療:市場規模與預測(2019年∼2024年)
  • 各產品的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2019年∼2024年)
  • 歐洲:市場規模與預測(2019年∼2024年)
  • 亞洲:市場規模與預測(2019年∼2024年)
  • 其他地區:市場規模與預測(2019年∼2024年)
  • 主要國家
  • 各地區的市場機會
  • 交易量成長要素-需求主導成長
  • 交易量成長要素-外部要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Endo International Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mylan NV
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR43955

Technavio has been monitoring the overactive bladder therapeutics market and it is poised to grow by $ 311.17 mn during 2020-2024 progressing at a CAGR of 2% during the forecast period. Our reports on overactive bladder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing number of drug approvals and strategic alliances. In addition, increasing number of drug approvals is anticipated to boost the growth of the market as well.

The overactive bladder therapeutics market analysis includes product segment and geographic landscapes

Technavio's ‘overactive bladder therapeutics market ’ is segmented as below:

By Product:

  • Anticholinergics
  • Beta-3 adrenergic agonists
  • Other OAB therapeutics

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the advent of combination therapy as one of the prime reasons driving the overactive bladder therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our overactive bladder therapeutics market covers the following areas:

  • Overactive bladder therapeutics market sizing
  • Overactive bladder therapeutics market forecast
  • Overactive bladder therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading overactive bladder therapeutics market vendors that include AbbVie Inc., Astellas Pharma Inc., Endo International Plc, Johnson & Johnson, Merck & Co. Inc., Mylan NV, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.. Also, the overactive bladder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Anticholinergics - Market size and forecast 2019-2024
  • Beta-3 adrenergic agonists - Market size and forecast 2019-2024
  • Other OAB therapeutics - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - Demand led growth
  • Volume drivers - External factors
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Endo International Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mylan NV
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Product - Market share 2019-2024 (%)
  • 22: Comparison by Product
  • 23: Anticholinergics - Market size and forecast 2019-2024 ($ million)
  • 24: Anticholinergics - Year-over-year growth 2019-2024 (%)
  • 25: Beta-3 adrenergic agonists - Market size and forecast 2019-2024 ($ million)
  • 26: Beta-3 adrenergic agonists - Year-over-year growth 2019-2024 (%)
  • 27: Other OAB therapeutics - Market size and forecast 2019-2024 ($ million)
  • 28: Other OAB therapeutics - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Product
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ million)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ million)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ million)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ million)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AbbVie Inc. - Overview
  • 50: AbbVie Inc. - Business segments
  • 51: AbbVie Inc. - Key offerings
  • 52: AbbVie Inc. - Key customers
  • 53: AbbVie Inc. - Segment focus
  • 54: Astellas Pharma Inc. - Overview
  • 55: Astellas Pharma Inc. - Business segments
  • 56: Astellas Pharma Inc. - Key offerings
  • 57: Astellas Pharma Inc. - Key customers
  • 58: Astellas Pharma Inc. - Segment focus
  • 59: Endo International Plc - Overview
  • 60: Endo International Plc - Business segments
  • 61: Endo International Plc - Key offerings
  • 62: Endo International Plc - Key customers
  • 63: Endo International Plc - Segment focus
  • 64: Johnson & Johnson - Overview
  • 65: Johnson & Johnson - Business segments
  • 66: Johnson & Johnson - Key offerings
  • 67: Johnson & Johnson - Key customers
  • 68: Johnson & Johnson - Segment focus
  • 69: Merck & Co. Inc. - Overview
  • 70: Merck & Co. Inc. - Business segments
  • 71: Merck & Co. Inc. - Key offerings
  • 72: Merck & Co. Inc. - Key customers
  • 73: Merck & Co. Inc. - Segment focus
  • 74: Mylan NV - Overview
  • 75: Mylan NV - Business segments
  • 76: Mylan NV - Key offerings
  • 77: Mylan NV - Key customers
  • 78: Mylan NV - Segment focus
  • 79: Ono Pharmaceutical Co. Ltd. - Overview
  • 80: Ono Pharmaceutical Co. Ltd. - Business segments
  • 81: Ono Pharmaceutical Co. Ltd. - Key offerings
  • 82: Ono Pharmaceutical Co. Ltd. - Key customers
  • 83: Ono Pharmaceutical Co. Ltd. - Segment focus
  • 84: Pfizer Inc. - Overview
  • 85: Pfizer Inc. - Business segments
  • 86: Pfizer Inc. - Key offerings
  • 87: Pfizer Inc. - Key customers
  • 88: Pfizer Inc. - Segment focus
  • 89: Sanofi - Overview
  • 90: Sanofi - Business segments
  • 91: Sanofi - Key offerings
  • 92: Sanofi - Key customers
  • 93: Sanofi - Segment focus
  • 94: Teva Pharmaceutical Industries Ltd. - Overview
  • 95: Teva Pharmaceutical Industries Ltd. - Business segments
  • 96: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 97: Teva Pharmaceutical Industries Ltd. - Key customers
  • 98: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations